Skip to main content
. 2015 Sep 28;6(32):33290–33305. doi: 10.18632/oncotarget.5396

Figure 1. Experimental design for evaluation of licofelone and gefitinib efficacy in PC prevention in GEM.

Figure 1

A–B. Structure of licofelone (A) and gefitinib (B) C. Experimental design for evaluation of licofelone, gefitinib, and a combination of licofelone (L) + gefitinib (G) efficacy in PC inhibition in male and female p48Cre/+-LSL-KrasG12D/+ GEM mice. At six weeks of age, groups of mice (24–34/group for activated p48Cre/+-LSL-KrasG12D/+ or 12/group for wild-type) were continuously fed AIN-76A diets containing 0, 250 ppm licofelone, or 100 ppm gefitinib, alone or in combination, for 38 weeks. Each pancreas was evaluated histopathologically for marker expression as described in the text. D-E. Effect of licofelone, gefitinib, or the combination on bodyweight (BW; means ± SE) at termination of the experiment in male D. and female E. mice. No statistically significant differences were observed between control and drug-treated p48Cre/+-LSL-KrasG12D/+ or wild-type mice.